Cargando…
FRI322 Lack Of Tumor Size Change With Long-term Cabergoline For Prolactinoma
Disclosure: S. Bendaram: None. V. Kantorovich: None. Introduction: Prolactinomas are the most common tumors of the pituitary gland and account for about 40% of all Pituitary adenomas, of which 10% are macroprolactinomas measuring >1 cm. Dopamine Agonists (DAs) normalize the prolactin levels and a...
Autores principales: | Bendaram, Snigdha Reddy, Kantorovich, Vitaly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554274/ http://dx.doi.org/10.1210/jendso/bvad114.1257 |
Ejemplares similares
-
FRI358 A Rare Cause Of SIADH: Leptomeningeal Deposits Metastatic From T-cell Proliferative Disorder
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2023) -
FRI321 Aggressive Prolactinoma Empirically Treated With Cabergoline Leading To Rapid CSF Leak
por: Yau, Alice, et al.
Publicado: (2023) -
LBODP079 A Case of Silent Invasive Corticotroph Adenoma
por: Bendaram, Snigdha Reddy, et al.
Publicado: (2022) -
FRI306 Natural History Of Untreated Prolactinoma
por: Sadek, Maryanne, et al.
Publicado: (2023) -
SAT-474 Giant Prolactinoma Case Series Assessing Response on Initial Dose of Cabergoline
por: Madan Paramasivan, Ameena, et al.
Publicado: (2019)